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1. INTRODUCTION 
According to World Health Organization (WHO), approximately 2.5 billion cases of 
diarrhea occurred worldwide which results in 1.5 million deaths among children under 
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the age of five. It is a common cause of death in developing countries and the second 
most common cause of infant deaths. Among the main causes,	Shigellosis is responsible 
of more than 165 million cases annually, leading to 1.2 million deaths [1]. Furthermore, 
many cases progress into serious damages in their intestinal epithelium that will limit 
the correct nutrient absorption with the subsequent sequel for life. Shigella spread 
massively within the community and from person to person, and hence, prevention 
relies on basic sanitary measures, which unfortunately may be not possible applied for 
many countries. In addition, the increasing problem of antibiotic resistance alerts on the 
urgent need of protective vaccines. In fact, the World Health Organization has made the 
development of a safe and effective vaccine against Shigella a high priority [1]. 
The efforts have been mainly focussed on live oral vaccines with several vaccine 
candidates on clinical trials [2]. However, development of such safe Shigella vaccine is 
being problematical, and no vaccine is still available[3].  
Currently, most vaccines in development are acellular vaccines which [2;4] in 
comparison to live-attenuated or whole inactivated organism, are safer. However, these 
prototypes require adjuvants to achieve a more effective immune response. The 
challenge is the designing of formulations able to enhance the immunogenicity of 
associated antigens, through the right activation of the immune system, and susceptible 
to be administered by mucosal routes. Previous studies of our group have evaluated the 
adjuvant capability of nanoparticles made from the copolymer of methyl vinyl ether and 
maleic anhydride (Gantrez AN®). These nanoparticles demonstrated their ability to 
initiate a strong and balanced mucosal immune response and then, to efficiently induce 
Th-1 subset [5]. In addition, these nanoparticles loaded with different antigens have 
showed to be effective against experimental challenges with Salmonella or Brucella [6-
9]. 
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In this work we propose the use of outer membrane vesicles (OMVs) from Shigella as 
the source of relevant antigens to be included in the acellular vaccine. OMVs are 
secreted from the outer membrane of a large variety of gram negative bacteria, during in 
vitro culture and during infection [10]. Currently, there have been described many 
functions for this blebbing process. Functions proposed vary from facilitating the 
intracellular bacterial growth within phagocytes [11], to the delivery of effectors 
molecules critical for pathogen dissemination such as pathogen-associated molecular 
patterns (PAMPs) and other virulence factors to host cells [12-14]. 
We therefore describe here the preparation, characterization and evaluation of Shigella 
flexneri outer membrane vesicles in order to be used in vaccination. We obtained the 
OMVs from S. flexneri 2a, being this the most common cause of shigellosis. In fact, it’s 
responsible for 25 to 50 percent of all cases in the developing world [2]. The protective 
efficacy of OMVs either in their free form or adjuvanted in NP were tested in the 
murine pneumonia model [15] after immunization with one single dose by intradermal 
or mucosal routes.  
 
The OMVs formulations obtained and characterized here were found to induce 
protection in mice after one single dose against a lethal dose of S. flexneri 2a.  
	
 
2. MATERIAL AND METHODS 
Preparation and characterization of outer membrane vesicles 
OMVs were obtained from S. flexneri 2a (clinical isolate from Hospital de Navarra, 
Pamplona, Spain). Vesicles were purified from a method adapted from Horstman and 
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Kuehn [16]. Bacteria were grown in LB broth overnight to early stationary phase. Then, 
bacteria were inactivated with a solution of binary ethylenimine and formaldehyde (6 
mM BEI- 0, 06% FA, 6 h, 37 ºC). BEI was prepared as a 0.1 M solution by cyclization 
of 0.1 M 2-bromoethylamine hydrobromide (Sigma) in 0.175 M NaOH solution for one 
hour following the method of Bahnemann [17]. Cells were removed by pelleting 
(10,000 × g, 10 min). Supernatant was filtered through a 0.45 μm Durapore PVDF filter 
(Millipore) and purified by ultradiafiltration via a 300-kDa tangential filtration 
concentration unit (Millipore). The retentate was freezed in order to induce larger blebs 
formed through reassociation of the smaller ones into multimicelles, as had been 
proposed previously [18]. Final product was recovered by centrifugation at 40,000 × g, 
2 h. Total protein content was determined by the method of Lowry, with bovine serum 
albumin as standard. Lypopolysaccharide (LPS) content was determined by Purpald 
assay[19;20]. Briefly, to 50 μL of LPS samples or standards [21] in each of the duplicate 
wells in a 96-well tissue culture plate, 50 μL of 32 mM NaIO4 was added, and the plate 
was incubated for 25 min followed by addition of 50 μL of 136 mM purpald reagent in 
2 N NaOH. After further incubation for 20 min, 50 μL of 64mM NaIO4 was added, and 
the plate was incubated for another 20 min. The foam in each well can be eliminated by 
addition of 20 μL 2-propanol. The absorbance of each well was measured by a plate 
reader at 550 nm. Finally, extract was resuspended in sample buffer 1× and analyzed by 
SDS-PAGE and immunoblotting, using polyclonal pool sera from patient infected with 
S. flexneri (Clínica Universidad de Navarra) or anti IpaC mAb (kindly provided by A. 
Phalipon, Institut Pasteur). The morphology of the vesicles was examined by Field 
Emission Scanning Electron Microscope. 
Outer membrane proteins (OMPs)  from S. flexneri were prepared by sequential 
detergent extraction of cell envelopes [18]. Briefly, after the disruption of cells by 
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sonication (4 pulses × 5 min, power 2, Branson Sonifier 450), whole bacteria were 
removed by centrifugation at 6000 × g, 15 min. Cell envelopes were recovered from 
supernatant by centrifugation (40 000 × g, 1h). Pellet was resuspended in 1% Sarkosyl 
(N-Lauryl sarcosine, Sigma Chemical Co., St. Louis, USA), incubated for 30 min and 
further centrifuged at 40 000g, 1h, twice. The enriched sediment in outer membrane 
proteins was suspended in 0.5 M Tris-HCl (pH 6.8) with 10% SDS (Lauryl sulfate, 
Sigma) and boiled for 15 min and finally, centrifuged (20 000 × g; 30 min). The OMPs 
of S. flexneri were present in the final supernatant. 
Ipa (invasion plasmid antigens) proteins secretion assay. Secretion of Ipa proteins 
through the TTSS (Type three secretion system) was induced using a Congo Red 
secretion assay [22]. Exponential-phase bacteria were harvested, resuspended in 10 μM 
Congo Red/PBS, and incubated at 37 ºC for 30 min. Following incubation, bacteria 
were pelleted by centrifugation, and supernatants were collected and passed through a 
0.22 μm-pore filter. Proteins in the supernatants, which represent proteins secreted 
through the TTSS, were then concentrated by tricholoroacetic acid precipitation. 
Finally, extract was resuspended in sample buffer 1× and analyzed by SDS-PAGE and 
immunoblotting using anti-IpaB or -IpaC mAb (kindly provided by A. Phalipon, Institut 
Pasteur). 
Preparation and characterization of nanoparticles 
Poly (anhydride) nanoparticles were prepared by a modification of the solvent 
displacement method [6;23]. Briefly, 100 mg of the copolymer of methyl vinyl ether 
and maleic anhydride (PVM/MA) (Gantrez®AN 119; M.W. 200 KDa) was dissolved in 
5 ml acetone under magnetic stirring at room temperature. On the other hand, 5 mg 
OMVs were dispersed by ultrasonication with a probe Microson TM (Misonix Inc., 
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New York, USA) in 10 ml water for 1 min. After dispersion, nanoparticles were formed 
by addition of this water phase containing OMVs. The agitation was maintained during 
15 min in order to allow the stabilization of the system. Organic solvents were removed 
under reduced pressure (Büchi R-144, Switzerland). The obtained nanoparticles were 
collected by centrifugation (27.000 × g, 20 min, 4 ºC) and washed with water twice. 
Finally, particles were freeze-dried using sucrose 5% as crioprotector. 
The preparation of empty nanoparticles was performed in the same way in the absence 
of OMVs. 
 
Characterization of nanoparticles. The particle size and the zeta potential of 
nanoparticles were determined by photon correlation spectroscopy (PCS) and 
electrophoretic laser Doppler anemometry, respectively, using a Zetamaster analyzer 
system (Malvern Instruments Ltd., Worcestershire, UK). The diameter of the 
nanoparticles was determined after dispersion in ultrapure water (1/10) and measured at 
25ºC by dynamic light scattering angle of 90ºC. The zeta potential was determined as 
follows: 200 μL of the samples was diluted in 2 mL of a 0.1 mM KCl solution adjusted 
to pH 7.4. The morphology of the vesicles was examined by Field Emission Scanning 
Electron Microscope (Carl Zeiss, model Ultra Plus). For this purpose freeze-dried 
formulations were resuspended in ultrapure water and centrifuged at 27,000 × g for 
20 min at 4 °C. Then, supernatants were rejected and the obtained pellets were mounted 
on TEM grids. The yield of the nanoparticles preparation process was determined by 
gravimetry as described previously [23]. Briefly, poly (anhydride) nanoparticles, freshly 
prepared, were freeze-dried. Then, the yield was calculated as the difference between 
the initial amount of the polymer used to prepare nanoparticles and the weight of the 
freeze-dried carriers. 
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Loading capacity of nanoparticles. The yield of nanoparticles was calculated from the 
difference between the initial amount of the polymer used to prepare the particles and 
the weight of the freeze-dried samples. The ability of PVM/MA nanoparticles to entrap 
the complex antigen was directly determined after degradation of loaded nanoparticles 
with NaOH. Briefly, OMVs-loaded Gantrez nanoparticles (15 mg) were dispersed in 
water vortexing 1 min. After centrifugation (27.000 × g, 15 min) pellet was resupended 
in NaOH 0,1 M sonicated (MicrosonTM Ultrasonic cell disruptor) and incubated for 1 h 
to assess the total delivery of the associated antigen. After this time, the amount of 
antigen released from the nanoparticles was determined using microbicin choninic acid 
(microBCA) protein assay (Pierce, Rockford, CA, USA). In order to avoid interferences 
of the process, calibration curves were made with degraded blank nanoparticles, and all 
measurements were performed in triplicate. 
Determination of the structural integrity and antigenity of OMVs. Western-blot 
analysis was used as a qualitative tool to examine the structure of the antigens, 
complementing the quantification performed by microBCA. To accomplish this 
analysis, the protocol for nanoparticle degradation was modified in order to avoid any 
interference of the enzyme. In this case, after nanoparticle isolation, 15 mg of loaded 
nanoparticles were dispersed in water vortexing 1 min. After centrifugation (27 000 × g, 
15 min) pellet was resupended in 2 ml of a mixed of dimethilformamide: acetone (1:3) 
(-80 ºC, 1h). After centrifugation, pellet was resuspended in acetone (-80 ºC, 30 min). 
Finally, extract was resuspended in sample buffer 1× and analyzed by SDS-PAGE and 
immunoblotting using polyclonal sera from hyperimmunized rabbit with S. flexneri 
[24]. 
SDS-PAGE and Immunoblotting 
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SDS-PAGE was performed in 12% acrylamide slabs (Criterion XT, Bio Rad 
Laboratories, CA) with the discontinuous buffer system of Laemmli and gels stained 
with Coomassie blue or silver staining. After electrophoresis, gels were electroblotted to 
a PVDF (polyvinylidene fluoride) membrane at 0.8 mA/cm2 for 30 min. Then, 
membranes were soaked overnight in a blocking solution containing 3% (w/v) of non-
fat milk and then incubated in the presence of different sera, described above. After the 
incubation, the membranes were washed five times; the anti-rabbit or human Ig-alkaline 
phosphatase conjugate was added, followed by incubation for an additional hour. The 
membranes were exhaustively washed and the antibody–antigen complexes were 
visualized after addition of the substrate/chromogen solution (H2O2/cloronaftol). 
Active immunization and challenge.  
All mice were treated in accordance with institutional guidelines for treatment of 
animals (Protocol 087/06 of animal treatment, approved in 1 October 2007 by the 
Ethical Comity for the Animal Experimentation, CEEA, of the University of Navarra). 
Nine-week-old BALB/c mice (20±1 g) were separated in randomized groups of 6 
animals and immunized with OMVs either free or encapsulated in PVM/MA NPs by 
intradermal, nasal, ocular (20 μg of extract) or oral route (100 μg of extract). The 
scheme of administration and doses are summarized in Table 1. 
Challenge infection was performed on day 35 intranasally with a lethal dose of 1×107 
UFC/Mouse of Shigella flexneri 2a (clinical isolate) grown to logarithmic phase and 
suspended in 20 µl of prewarmed PBS. The number of dead mice after challenge was 
recorded daily. 
 
Measurement of immune response in the mouse.  
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Blood samples were collected from the reto-orbital plexures of anesthetized mice  
ELISA. The antibody response was measured by an enzyme-linked immunosorbent 
assay (ELISA). In brief, 96-well microtiter plates (MaxiSorb; Nunc, Wiesbaden, 
Germany) were coated with 100 uL of 10 μg/ml OMVs in coating buffer (60 mM 
carbonate buffer, pH 9.6). Afterwards, unspecific binding sites were saturated with 3% 
bovine serum albumin (BSA) in PBS for 1 h at RT. Sera from mice were serially diluted 
in PBS with 1% BSA and incubated overnight at RT. After intense washing with PBS 
Tween 20 (PBS-T) buffer, the alkaline phosphatase (AP)-conjugated detection antibody, 
class-specific goat anti-mouse IgG/IgA (Sigma) for sera, was added for 1h at 37ºC. The 
detection reaction was performed by incubating the sample with ABTS substrate for 20 
min at room temperature. Absorbance was measured with an ELISA reader (Sunrise 
remote; Tecan-Austria, Groeding, Austria) at a wavelength of 405 nm. 
Quantification of cytokines from sera. Cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12(p40), IL-12(p70), IL-13, IL17, IFN-, and tumor necrosis factor) were quantified 
from serum by luminex-based multiplex assay (Milliplex; Millipore, Billerica, MA) 
using a Bioplex analyzer (Bio-Rad, Hercules, CA). 
Statistics  
Statistical analyses were performed using GraphPad Prism 5 for Mac OS X. All 
experiments were performed with n=6. Statistical comparisons between antibody serum 
levels were performed using Kruskal-Wallis test, followed by Dunn´s post-hoc test. The 
statistical significance was set at P < 0.05. For cytokine levels, it was performed using 
single-factor analysis of variance, followed by Turkey´s post hoc test. The statistical 
significance was set at P<0.001. The Kaplan-Meyer curves were used for analysis of the 




Isolation and characterization of Shigella flexneri OMVs.  
The scanning electron microscopy showed that the OMVs secreted in vitro by S. 
flexneri were spherical, with an average diameter of 50 nm (Fig. 1A). The yield 
obtained was 18 ± 0, 04 μg/ mg determined after lyophilisation and referred to the 
original cell culture dry weight. Quantitative analysis showed that protein content was 
54.52 ± 3.2 %, whereas the LPS content was 37.6  4.8 %.  A comparative SDS-PAGE 
analysis of the OMVs revealed that contained proteins corresponded to the OmpA, 34 
KDa; OmpC/OmpF, 38/42 kDa; VirG, 120 KDa (Fig. 2) already described by other 
authors as the main inmunodominant antigenic proteins [25;26]. As expected, the outer 
membrane protein enriched fraction and the purified OMVs showed a similar profile. 
Furthermore, OMVs contained bands at 62 KDa, 42 Kda and 38kDa that correspond 
with IpaB, IpaC and IpaD respectively (Fig. 2) [27]. Immunoblot assay using a 
monoclonal antibody specific to IpaB or IpaC demonstrated that these proteins were 
located on vesicles (Fig. 2), confirming the observation of Kadurugamuwa and 
Beveridge [28] . 
 
Characterization of OMVs-containig nanoparticles 
The yield of the OMV antigen-loaded NPs manufactured in relation to the initial 
amount of polymer employed was consistent (89%). Vaccine formulations were 
homogeneous and spherically shaped (Fig 1A). The average size of NP-OMV was 197 
nm with a polydispersity index of 0.06.  
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The Z potential of NP was tested before and after OMV encapsulation. Results suggest 
that OMV is at least partially bound on the NP surface, indicated by the change in Z of 
NP. Zeta potential of free OMVs was -14.1 +/- 3 mV. The encapsulation of the extract 
in nanoparticles resulted in a change of Z potential from -44 +/- 4 mV to -27 +/- 4 mV 
when OMVs were loaded into PVM/MA nanoparticles.  
To further confirm OMV encapsulation into NPs, BCA protein determination and SDS-
PAGE/immunoblotting were also performed. The procedure involved the use of a 
purification step in order to discard unbound OMV. S. flexneri OMVs were efficiently 
associated with PVM/MA nanoparticles, as they showed a loading encapsulation of 20 
g OMVs/ mg of polymer. Besides, an immunoblotting was carried out using sera from 
rabbit hyper-immunized with S. flexneri. Results indicate that entrapment in 
nanoparticles did not alter its antigenic properties (Fig. 1B). 
 
Evaluation of the immunogenicity and protection conferred by OMVs vaccine.  
Groups of 6 mice were immunized once by intradermal or mucosal routes with OMVs 
(20 µg/mouse), either free or encapsulated in NPs. A control group of non-immunized 
mice was also included. All animals immunized by nasal or ocular routes remained in 
good health, exhibiting no respiratory difficulties, changes in body temperature, or 
abnormal behaviour. Oral immunized mice showed a transient abdominal swelling a 
few hours after immunization. By contrast, mice immunized intradermally 
experimented sweating and lethargy during 2 days post-immunization, which 
disappeared thereafter. 
Specific IgG2a and IgG1 against OMVs antigens were determined by indirect-ELISA at 
days 0, 15 and 35 post-immunization (Fig. 3).  Results expressed that the OMV 
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immunization by either route elicited significant levels of serum IgG1 and IgG2a with 
respect control mice (Fig. 3). Higher levels of IgG were found in groups immunized 
intradermally. Overall the levels of IgG2a (Th1 response) were higher than that those of 
IgG1 (Th2).  An adjuvant effect after encapsulation was observed on the 
immunogenicity (global specific antibody response) especially after oral immunization. 
There were not found significant differences in the mucosal levels of the IgA elicited 
after intradermal or mucosal deliveries.  
Levels of serum cytokines were determined at day 15 post-immunization (Fig. 4).  The 
encapsulation of OMVs in NPs induced an increase in the level of IL-12 (p40) and a 
decrease of IL-10 with respect to the free form, by intradermal or oral delivery. In 
contrast, after ocular or nasal immunization, the inverse switching phenomenon was 
observed. 
At day 35 after immunization, mice were challenged with S. flexneri via intranasal route 
and monitored for survival over 30 days (n = 6 mice/group) (Fig. 5). Nasal or ocular 
immunizations with free OMVs provided complete protection. Non-significant 
differences were found between OMV free or nano-encapsulated in groups immunized 
by nasal, ocular or oral route. In contrast, the intradermally delivery of free OMVs was 
not protective, while the encapsulated extract conferred full protection.  
 
4. DISCUSSION 
Currently, live vaccines provide better protection as compared to the inactivated 
vaccines, including the acellular ones[2;29]. However, it is always difficult to properly 
calibrate attenuation to achieve the minimum of toxicity with the optimal 
immunogenicity. Besides, the use of live Shigella vaccines is questionable since this 
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pathogen is able to strongly interfere with the immune response, by inducing an 
immunosuppressive condition that favors infective process. In our present experimental 
study, we support the use of mucosal immunization with acellular vaccines. Results 
demonstrated a significant efficacy and no reactogenicity in the mice pulmonary model. 
The best prophylactic measure probably would be to prevent bacterial invasion by 
neutralizing key surface virulence factors. The outer membrane (OM) of Shigella 
contains several main virulence factors, including outer membrane proteins (OMP), 
protein adhesins, the highly conserved virulence-plasmid-encoded Ipa proteins [28] as 
well as LPS. These are essential components in the invasion process, and can alter the 
course of infection and the host responses, and therefore their neutralization for the host 
will succeed in protective immunity. [25;30-33]. 
Outer membrane vesicles (OMVs) consist of OM and soluble periplasmic components 
shed from gram-negative bacteria. This blebbing process is considered as a peculiar 
bacterial extracellular secretion system than enable bacterial colonization and impairs 
host immune response [34]. Therefore, it is plausible to think on Shigella OMVs as 
ideal candidates for an acellular vaccine. The capacity of OMV-based vaccines to 
stimulate a protective immune response has already been exploited against several 
bacterial pathogens, such as Brucella ovis [18], S. typhimurium [35], Flavobacterium 
[36] Porfiromonas [37] or Neisseria meningitides B, with over 55 million doses 
administered to date of the former [38].  
As many gram-negative bacteria, Shigella bleb off membrane vesicles during normal 
growth. Kadurugamuwa, et al. already obtained and characterized membrane vesicles 
from S. flexneri [39]. In order to obtain this material massively, we developed an 
extraction protocol that also maximize OMV purity. Vesicles were isolated from 
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concentrated, cell-free culture supernatant leading to an appropriate antigenic profile as 
well as high purity grade. Besides, final product was ultradiafiltered in order to avoid 
interferences in the encapsulation process.  
OMV used here contain key alarm signals such as LPS, OMPs and Ipa recognized by 
the innate immune system, including epthelial cells, MALT and antigen presenting 
cells[40;41], and therefore have the capacity to either enhance bacterial clearance or 
cause host tissue damage by activating an inflammatory response. It is interesting to 
note that these components provide a prolonged stimulation of the inflammatory 
response that, at first instance, facilitates bacterial survival in the tissues. However, this 
fact will lead to the bacteria elimination by the host immune system[42].  
In fact, our results indicate that a single dose of non-adjuvated OMVs delivered by 
mucosal routes is able to protect against a lethal challenge with S. flexneri. Vaccines 
that stimulate protective mucosal immune responses often need an adjuvant for proper 
delivery and presentation to the mucosal immune tissues. The mechanisms underlying 
the effectiveness of free OMV without external adjuvant may be explained by the nature 
of some individual components contained within this “proteoliposome” or/and by the 
biophysical properties of these vesicles [43]. Besides, Ipa containing OMVs may 
contribute to its adjuvanticity by their ability to interact with host cell receptors which 
facilitate OMVs transcytosis across mucosal epithelial barriers [27]. On the other hand, 
the amphipatic properties of OMVs may facilitate its own movement through mucosal 
tissues, enhancing antigen presentation to drive a protective response. 
 
In this study, we measured the levels of cytokines in OMVs vaccinated mice two weeks 
after the immunization. Then, we analyzed their association with the challenge outcome. 
A strong association between the ratio of IL-12p40/ IL-10 and protection was found. 
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Moreover, low levels of IFN-γ correlated with protection. However, conclusions from 
these particular data must be taken with caution since cytokine levels were measured 
directly from serum. At this point, further studies are being carried out to really 
establish a correlation of these parameters and protection. 
After oral administration, under steady-state conditions, some factors released by 
enterocytes, such as retinoic acid, thymic stromal lymphopoietin and TGF-β, will 
“condition” non-activated resident DCs to elicit a Th2 or regulatory responses [44]. 
However, following an inflammatory stimulus, a recruitment of DC expressing 
CX3CR1 to the mucosal tissues is observed, increasing the number of DC extending 
dendrites into intestinal lumen.  Under this state of high activation, DC-expressing 
massively co-stimulatory molecules, present the antigenic determinant to the specific T 
naïve cells in the T area MALT. The substantial distinctive release of IL-12 from those 
DCs will also contribute to the further differentiation of naïve cells to Th1/Th2/Th17, 
linked to an inflammatory response. Actually, our results would support it since OMVs 
adjuvanted into NPs induced increasing levels of IL-12 (p40) and decreasing IL-10 with 
respect to the free form, either by intradermal or oral delivery. NPs can enhance the 
delivery of the loaded antigen to the gut lymphoid cells due to their ability to be 
captured and internalized by cells of the gut-associated lymphoid tissue (GALT), and to 
induced maturation of DCs with a significant upregulation of CD40, CD80, and CD86 
and a Th1 response in animal models. The mechanisms responsible for DC maturation 
may be related to TLR-NP specific interaction [5]. 
 On the other hand, the encapsulation of OMVs in NPs induced an increase in the level 
of IL-10 and a decrease of IL-12 (p40) with respect to the free form, by ocular or 
nasal routes, which is characteristic of mucosal adjuvants that usually stimulate a Th2 
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T-cell response [45-47], characterized by increased secretory IgA, high proportions of 
antigen-specific serum IgG1, and the stimulation and synthesis of IL-4, IL-5, and IL-10.  
The specific immune mechanisms that mediate resistance to Shigella infection have not 
been clearly defined and are currently being debated. Thus, in humans, up regulation of 
both proinflammatory and anti-inflammatory are observed during the first stages of 
infection. Later, in relation with the convalescent stage of shigellosis, an increase in 
IFN-γ is observed. Summing up, although Th1 is effective to control infection, a Th2 
response may be also as effective but shorter-lasting. 
Concerning the antibody response elicited after OMV immunization, we can not 
establish a relation between antibody levels and protection. Serum and mucosal 
antibodies to LPS and the Ipa proteins have been demonstrated during human 
shigellosis [48;49]. However, it has not been established the role of these antibodies to 
limit the spread or severity of the infection. The apparent inconsistency between IgG 
subclass response and cytokine profile may be due to immune cells other than T helper 
cells.  
The ultimate goal for vaccination is to stimulate long-lasting protective immunological 
memory. Toll-like receptors [50] generally promote adaptive immune responses 
indirectly by activating innate immune cells. It has been recently shown that the use of 
multiple TLR-agonists carried by nanoparticles influence in the induction of long-term 
memory cells [51]. 
Recent studies report that in a murine model of acute bacterial infection with S. flexneri 
the T cell response is dominated by the induction of long-term memory Shigella-
specific Th17 cells that contribute to mediate protective immunity against reinfection 
[52]  
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Now, new research shows an unexpected direct role for TLR2 signalling in T cells 
themselves, promoting the differentiation and proliferation of T helper 17 (TH17) cells 
[50]. Taking into account these data and  together with previous results from our own 
group about the high ability of PVM/MA to stimulate TLR2 [5] suggest that these 
nanoparticles are good adjuvant candidate for further investigation. OMVs are safe and 
protective in mice, therefore, the use of OMVs adjuvanted into NP to trigger mucosal 
immunity and effectively neutralize Shigella infection open the door to safely deals with 
vaccination, especially critical when young children are the primary target.  
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Figure 1. (A). Scanning electron micrograph images of outer membrane vesicles 
(OMVs) from Shigella flexneri 2a (up), or loaded in nanoparticles (NP-OMVs) (down). 
Scale bar indicates 200 nm. (B) Integrity and antigenicity of the outer membrane 
vesicles components antigenic components after encapsulation into nanoparticles. 
Panel shows the immunoblotting developed with a pool of sera from rabbit 
hyperimmunized with whole cells from Shigella flexneri: lanes correspond with the 
following samples: (1) free OMVs, (2) OMVs released from OMV-loaded NPs.  
 
Figure 2. Comparative analysis of Shigella flexneri outer membrane vesicles. SDS-
PAGE with silver staining for proteins (A) or for LPS (B), and immunoblotting (C) of: 
(1) outer membrane vesicles (OMVs), (2) extract enrich in outer membrane proteins 
(OMPs), and (3) extract enrich in Ipa proteins. Immunoblots were developed with 
polyclonal antibodies from a patient infected with S. flexneri (lane a), anti-IpaC mAb 
(lanes b) and anti-IpaB mAb (lane c). Molecular weight markers and identity of some 
bands are indicated. 
 
Figure 3. Antibody immune response induced after vaccination of BALB/c mice. 
Serum IgG1, IgG2a and IgA titers in vaccinated mice (n=6/group) with either free 
extract (OMVs) or loaded in nanoparticles (NP-OMVs) at weeks 0, 2 and 5 after 
immunization. Broken line indicates first dilution tested. Data are mean value (*, P < 0, 
05 for immunized mice vs. control).  
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Figure 4. Immune response induced after vaccination of BALB/c mice. Cytokines 
serum level (IL-10, IL-12 (p40), IL-12 (p70), IL-5, and IFN-) detected at day 15 after 
immunization with either free outer membrane vesicles (OMVs) (gray bars) or loaded in 
nanoparticles (NP-OMVs) (black bars). Broken line indicates serum level before 
immunization. Data are mean value (*, P < 0,001).  
 
Figure 5. Protection study against Shigella flexneri. BALB/c mice (20 ±1 g) were 
immunized with 20 μg of outer membrane vesicles either free (OMVs) or loaded into 
nanoparticles of PVM/MA (NP-OMVs) by intradermal (■), nasal (▲), ocular (   ) or 
oral (♦), routes. An extra group was included as non-immunized control (×). At day 35 
after immunization, all groups received an intranasal lethal challenge of 107 UFC/mouse 
of Shigella flexneri 2a (clinical isolate). Graphs indicate the percentage of mice that 
survived the infective challenge at the indicated days after immunization (*, P<0, 01, 
Logrank test) 
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